The U.S. Food and Drug Administration (FDA) approved digital breast tomosynthesis (DBT) in 2011. Given how effectively DBT detects cancer, it may eventually become the new gold standard in breast imaging. 2022 October 4, “Tomosynthesis”, in Cleveland Clinic, archived from the original on 13 Feb 2025: